Update on the role of copanlisib in hematologic malignancies.Clinical research in hematologic malignancies is continually advancing with emerging concepts in therapy and evolving results from clinical protocols.  Copanlisib is a pan-PI3K inhibitor currently FDA-approved for the treatment of relapsed/refractory follicular lymphoma (FL) following two lines of therapy.  Since FDA approval, there have been further investigations into the long-term safety profile of copanlisib, as well as treatment of FL and other lymphoma subtypes, both indolent and aggressive.  The use of copanlisib as part of a combination therapy for various hematologic malignancies will also be discussed.  Copanlisib is a unique drug compared with other PI3K inhibitors, with remarkable potential to improve our armamentarium in cancer treatment.
copanlisib
Update on the role of copanlisib in hematologic malignancies.Clinical research in hematologic malignancies is continually advancing with emerging concepts in therapy and evolving results from clinical protocols.  Copanlisib is a pan-PI3K inhibitor currently FDA-approved for the treatment of relapsed/refractory follicular lymphoma (FL) following two lines of therapy.  Since FDA approval, there have been further investigations into the long-term safety profile of copanlisib, as well as treatment of FL and other lymphoma subtypes, both indolent and aggressive.  The use of copanlisib as part of a combination therapy for various hematologic malignancies will also be discussed.  Copanlisib is a unique drug compared with other PI3K inhibitors, with remarkable potential to improve our armamentarium in cancer treatment.
copanlisib
Update on the role of copanlisib in hematologic malignancies.Clinical research in hematologic malignancies is continually advancing with emerging concepts in therapy and evolving results from clinical protocols.  Copanlisib is a pan-PI3K inhibitor currently FDA-approved for the treatment of relapsed/refractory follicular lymphoma (FL) following two lines of therapy.  Since FDA approval, there have been further investigations into the long-term safety profile of copanlisib, as well as treatment of FL and other lymphoma subtypes, both indolent and aggressive.  The use of copanlisib as part of a combination therapy for various hematologic malignancies will also be discussed.  Copanlisib is a unique drug compared with other PI3K inhibitors, with remarkable potential to improve our armamentarium in cancer treatment.
copanlisib
There are currently four United States Food and Drug Administration (FDA)-approved PI3K inhibitors, with several others in development.  Copanlisib is a pan-PI3K inhibitor currently FDA-approved for the treatment of relapsed/refractory follicular lymphoma (FL) following two lines of therapy.  Since FDA approval, there have been further investigations into the long-term safety profile of copanlisib, as well as treatment of FL and other lymphoma subtypes, both indolent and aggressive. 
FDA
Update on the role of copanlisib in hematologic malignancies.Clinical research in hematologic malignancies is continually advancing with emerging concepts in therapy and evolving results from clinical protocols.  Copanlisib is a pan-PI3K inhibitor currently FDA-approved for the treatment of relapsed/refractory follicular lymphoma (FL) following two lines of therapy.  Since FDA approval, there have been further investigations into the long-term safety profile of copanlisib, as well as treatment of FL and other lymphoma subtypes, both indolent and aggressive.  The use of copanlisib as part of a combination therapy for various hematologic malignancies will also be discussed.  Copanlisib is a unique drug compared with other PI3K inhibitors, with remarkable potential to improve our armamentarium in cancer treatment.
copanlisib